Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7006858 | 0.88 | SMPD1 (0.41) | SMPD1LPAR3LPAR1LPAR2 | |
| SCHEMBL3202115 | 0.82 | TSHR (0.31) | — | |
| SCHEMBL11245641 | 0.78 | SMPD1 (0.37) | SMPD1LPAR3LPAR1LPAR2 | |
| SCHEMBL9729488 | 0.78 | SMPD1 (0.37) | SMPD1LPAR3LPAR1LPAR2 | |
| SCHEMBL17417120 | 0.72 | LPAR2 (0.32) | SMPD1LPAR3LPAR2 | |
| SCHEMBL11208828 | 0.72 | SMPD1 (0.33) | SMPD1 | |
| Phosphoric Acid SCHEMBL7079258 | 0.72 | SMPD1 (0.30) | SMPD1 | |
| SCHEMBL5982297 | 0.70 | SMPD1 (0.32) | SMPD1 | |
| SCHEMBL10422584 | 0.70 | SMPD1 (0.32) | SMPD1 | |
| SCHEMBL433467 | 0.69 | SMPD1 (0.43) | SMPD1LPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115888415-A | Preparation method of nanofiltration membrane and nanofiltration membrane prepared by same | 沃顿科技股份有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-114583383-B | Heat-resistant flame-retardant composite diaphragm and preparation method and application thereof | 潍坊科技学院 | 2023-10-31 | — | — | CN | disclosed |
| CN-115888415-A | Preparation method of nanofiltration membrane and nanofiltration membrane prepared by same | 沃顿科技股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-8318933-B2 | Process for preparing rosuvastatin calcium | AUROBINDO PHARMA LTD (IN) | 2012-11-27 | — | — | US | disclosed |
| US-20100048899-A1 | PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LTD (IN) | 2010-02-25 | — | — | US | disclosed |
| EP-2079712-A2 | AN IMPROVED PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LIMITED (IN) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008053334-A2 | AN IMPROVED PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LIMITED (IN) | 2008-05-08 | — | — | WO | disclosed |
| WO-2007004049-A1 | OXAZOLIDINONES CONTAINING AZETIDINE AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006076845-A1 | PROCESS FOR PRODUCING ROSUVASTATIN CALCIUM, INTERMEDIATE FOR THE PREPARATION OF THE SAME AND PROCESS FOR PRODUCING THE INTERMEDIATE | ANHUI QINGYUN PHARMACEUTICAL AND CHEMICAL CO., LTD (CN) | 2006-07-27 | — | — | WO | disclosed |
| EP-1057814-B1 | TETRAHYDROBENZINDOLE DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2005-03-09 | — | — | EP | disclosed |
| US-6498251-B1 | Tetrahydrobenzindole derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| US-6407112-B1 | 2A,3,4,5-TETRAHYDRO-1H-BENZ(CD)INDOL-2-ONE DERIVATIVES; 5-HYDROXYTRYPTAMINE AGONISTS; SLEEP, CIRCADIAN RHYTHYM, BIPOLAR, AND PSYCHOLOGICAL DISORDER TREATMENT | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1081136-A1 | OPTICALLY ACTIVE TETRAHYDROBENZINDOLE DERIVATIVES | Meiji Seika Kaisha, Ltd. (JP) | 2001-03-07 | — | — | EP | disclosed |
| EP-1057814-A1 | TETRAHYDROBENZINDOLE DERIVATIVES | Meiji Seika Kaisha, Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| US-5607670-A | 8,10-PENTADECADIEN-1-OL AND 9-PENTADECEN-1-OL ACETATE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1997-03-04 | — | — | US | disclosed |
| US-4622401-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-11-11 | — | — | US | disclosed |
| EP-0070376-A1 | Heterocyclic substituted-amino-pyrazolines | AMERICAN CYANAMID COMPANY (US) | 1983-01-26 | — | — | EP | disclosed |
| US-4347251-A | ANTIINFLAMMATORY, ANALGESICS, BACTERICIDES, FUNGICIDES | AMERICAN CYANAMID COMPANY (US) | 1982-08-31 | — | — | US | disclosed |
| US-4282223-A | ANTIDEPRESSANTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048899-A1 | PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | CACNA1I, CACNA1S, CACNA1F | SMPD1 469/4885LPAR3 1821/4885LPAR1 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.